IFNA1 and neoplasm: IFN-based therapies such as ropeginterferon alfa-2b bind to receptors and activate tyrosine-kinases JAK1 and another JAK family member TYK2, activating STAT and non-canonical pathways to activate downstream growth-regulatory proteins to inhibit the tumor cell growth and transformed phenotype.